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ABSTRACT 
Gene expression can be modified in a wide variety of ways, out of which the 
gene delivery via plasmids (pDNA) is considered as the most basic. In addition 
to the gene expression, post-transcriptional silencing through the RNA inter-
ference may provide a gene alteration method with high specificity and effi-
ciency. Small interfering RNAs (siRNA) are oligonucleotides (ONs) that occur 
naturally in the cells as a part of a silencing mechanism and introducing an 
extracellular siRNA into the cells could be used to achieve a therapeutic effect. 
Besides gene expression and silencing, it is possible to modulate pre-mRNA 
splicing. For this, splice-correction antisense ONs (SCOs) could be used. 
Unfortunately, the chemical and the physical properties of the nucleic acid (NA) 
molecules narrow the use of NAs and a delivery method or a vector is needed to 
enable them to cross the membranes of the cells and reach their full potential. 
Cell-penetrating peptides (CPPs) are one type of vectors with high potential for 
the delivery of NAs. CPPs are short sequences consisting of approximately  
5–30 amino acids (aa-s) with the ability to cross the membranes of the cells and 
carry along the associated cargoes.  
In this thesis the role of modifications in the CPP sequence to the complex 
formation is investigated. Complexes are formed between the CPPs belonging 
to the NickFect or PepFect family and the NA cargo. The physico-chemical 
properties, internalization into the cells and intracellular trafficking of the 
formed CPP/cargo complexes are examined to understand the properties a CPP 
or a complex needs to achieve high biological effect from the delivered cargo. 
As the characteristics of the CPP/cargo complexes rely on the CPP and also the 
cargo it has to deliver, different types of NA are used: pDNA, siRNA and SCO. 
All the processes related to complex formation and interactions are determined 
in cell free and in in vitro conditions. 
Taken together, our results demonstrate that although being all stearyl-
transportan10 modifications, the NA delivery mechanisms and capabilities dif-
fer between the tested CPPs. In addition, the delivery process of different types 
of NAs poses diverging challenges to the delivery vector. 
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INTRODUCTION 
Gene therapy and genetic engineering have opened new approaches in the 
alteration of genes, with the aim of curing diseases or introducing new traits to 
the cells. Different nucleic acid molecules, including plasmids, SCOs, siRNAs, 
etc. could be used for it. Still, because of the high charge density, large size and 
lack of intrinsic internalization route to gain access to the cells, NAs have not 
yet reached their full therapeutic potential. The development of an efficient, 
biocompatible and non-toxic delivery method is the basis for broader use of the 
NAs.  
Viral vectors are considered the most efficient delivery method this far, but 
several concerns related to their safety have led to the development of non-viral 
methods that are broadly divided into chemical and physical methods. These 
methods include the use of microinjections, lipid-based delivery vectors, 
cationic delivery vectors and CPPs. CPPs are short sequences consisting of 
approximately 5˗30 aa-s and have the unique ability to gain access into the cell 
interior and carry into the cells the cargo attached to them. Although using the 
CPPs have some limitations, understanding the interactions between the CPP 
and the cargo, the structure and interactions with the cell of the formed nano-
particles, as well as intracellular trafficking of the latter give the basis upon 
which further development of the CPP-based carriers may proceed. 
Plasmid DNA is a large circular DNA molecule from which a desired gene 
can be expressed when delivered to the cell nucleus. The size and the abundance 
of negative charges require condensation of the plasmid molecule by the de-
livery vector, before it can be efficiently protected from nucleases and delivered 
into the cell. They are one of the most commonly used NAs in biotechnology 
because of their versatility and ease of production. Small interfering RNA mole-
cules are small, double stranded NAs with terminal overhangs susceptible to 
enzymatic degradation. Splice-correction ONs (SCOs) are antisense ONs that 
can be used to modulate splicing patterns. They are single-stranded and easily 
degraded by enzymes. Because of intrinsic difference of siRNA, SCO and 
pDNA, the properties expected from the carrier diverge. In order to develop the 
most effective transporters for the specific purposes, it is essential to understand 
the CPP-cargo interactions, complex formation and stability in addition to inter-
nalization and intracellular trafficking of the CPPs with different cargoes. 
This thesis is dedicated to the investigation of the CPP-based delivery 
vectors for the complex formation with the NAs and their transport into the 
cells. The CPPs used in this thesis enable the use of the non-covalent strategy 
for CPP/NA nanoparticle formation and are thoroughly studied for complex 
stability to the premature dissociation and delivery of CPP/cargo complexes in 
vitro. 
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1. REVIEW OF LITERATURE 
1.1. Gene therapy and genetic modification by nucleic acids 
Gene therapy is a method that uses NA molecules as a drug in order to alleviate 
diseased state, improve the life quality of the patient or cure a disease perma-
nently [1]. Genetic modification is the transfer of genetic material to introduce 
novel or improved organisms and also produce a gene product naturally not 
occurring in that cell [2]. Virtually all cells contain genes making them a poten-
tial target for gene alteration, if needed. There are various NAs that can be used 
for gene therapy. Based on their mechanism of action, they can be broadly 
divided into gene inhibitors, gene replacers or gene vaccines [3]. In addition to 
these, splicing patterns can be manipulated with SCOs. Genetic alteration of 
somatic cells could be achieved by manipulating the cells residing within the 
individual´s body (in vivo) or manipulating the cells obtained from the indi-
vidual (ex vivo) and subsequently returning it to the host [4]. For both 
approaches the NA has to reach the target cell, be taken up by the cell and pre-
sent bioactivity after reaching the intracellular target. For this, it has to over-
come several barriers depending on the administration route and the intra-
cellular target site for the NA. One of the setbacks of using NAs as drugs is 
their low stability to degradation, low membrane permeability, high charge den-
sity and the lack of efficient cellular uptake mechanism [5]. The success of gene 
therapy is largely dependent on the development of a vector or a transport 
vehicle that can selectively and efficiently deliver a NA to the target cells with 
minimal toxicity. In addition to increasing delivery efficacy, improving the 
genetic cargoes could result in a need for lower doses of the NA. 
 
 
1.1.1. Gene delivery 
Plasmids are circular DNA molecules, residing separately from the genomic 
DNA and are naturally found in the bacterial cells. They are a common kind of 
NA molecule to transfer genetic information into the cells, including eukaryotic 
cells, for gene therapy or for the production of a protein or RNA. The delivery 
of pDNA is one of the most basic techniques of molecular biology and a tech-
nological basis for in vitro and in vivo gene therapy. Only a few plasmids per 
cell are needed to have sufficient gene expression [6]. Gene transfer via pDNA 
has the potential to treat hereditary disorders and diseases that are caused by a 
combination of environmental factors and genetic predisposition [7]. 
Plasmids are generally considered non-toxic. They have low integration rate 
into the host´s genome, unless specifically engineered to do so. They exhibit a 
low specificity to a cell/tissue type, but by using distinct promoters and enhancers 
their specificity can be increased. Mainly a non-covalent vector-pDNA com-
plexation strategy is used, because the circular pDNA lacks a site where a 
covalent linker could be added. Compared to other NAs, plasmids are several 
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times bigger, ranging from less than 1 kbp (minicircles) to tens of kbp-s. They 
carry high density of negative charges in the backbone per plasmid. The size 
and the charges make the condensation of the plasmid into a small nanoparticle 
and at least a partial neutralization of the negative charges one of the crucial 
steps in the delivery through the negatively charged phospholipid bilayers. The 
pDNA has to be delivered to the cell nucleus or into the cytosol of diving cells, 
because the expression of a gene from the pDNA uses host´s cell transcription 
and translation mechanisms. In the cytosol, the free pDNA may be recognized 
as a foreign substance and taken up by lysosomes (Lys) as a part of autophagy 
[8], a process possible and important in many physiological processes [9]. 
When still bound to a carrier after reaching the cytosol, the routing to lysosomes 
can be overcome or at least, postponed. 
 
 
1.1.2. Splice correction by SCOs 
Post-transcriptional modifications such as splicing are precicely regulated fun-
damental processes in the cells for generating an mRNA that can be translated 
into a protein. The splicing of the pre-mRNA requires the recognition of the 
splice site following the assembly of the spliceosome. Spliceosome is a multi-
component splicing complex, which catalyzes the cut-and-paste reactions that 
cleave the introns and re-joinin the exons. Alternative splicing of the pre-
mRNA contributes to the functional diversity of the human genome. Abnor-
malities in the splicing may cause or contribute to the development or mainte-
nance of numerous diseases [10]. The use of antisense ONs to modify expres-
sion patterns of the alternatively spliced mRNAs is an approach for potentially 
controlling such diseases.  
SCOs are single stranded antisense NAs with the lenght of 15–20 nucleo-
tides. They are able to hybridize with specific complementary sequences in the 
pre-mRNA and they can be applied to promote exon skipping in the spliceo-
some. Their use is limited due to their fast degradation by nucleases in the 
extracellular and intracellular environment. 
 
 
1.1.3. RNA interference 
RNA interference (RNAi) is a common process in the cells with the aim of in-
hibiting the expression of a gene. One of the advantages of using RNAi is the 
high target specificity facilitated by the base pairing between the target mRNA 
and the therapeutic ON [11]. The therapeutic ONs for inducing RNAi include 
antisense ONs, short hairpin RNAs, siRNAs, single-stranded RNAs and 
aptamers. The potential for RNAi therapeutics is very broad and is currently 
limited by the lack of an efficient delivery technology [12].  
Synthetic siRNAs are small, double stranded NA molecules with terminal 
overhangs and a number of solvent-exposed negative charges. They can be 
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attached to the delivery vectors covalently or non-covalently. The low bio-
logical effect in vivo of the covalently linked siRNA has led to more frequent 
use of the non-covalent strategy [13, 14]. Still, linking via electrostatic inter-
actions may result in the instability of the nanocomplexes and premature release 
of the cargo. The terminal overhangs of linear ONs are more susceptible for 
enzymatic degradation than circular pDNA. The small size and stiffness of 
siRNA molecules may help them to retain their initial structure. Therefore 
siRNAs do not necessarily require condensation to form a nanoparticle, as 
opposed to large pDNA molecules [15]. As an advantage compared to pDNA, 
inducing RNAi by siRNAs needs only the delivery of intact siRNAs into the 
cytosol.  
The transport vector for siRNA must be able to deliver intact cargo from the 
site of application to the cell surface, across the plasma membrane to the cyto-
plasm, and then to the target RNA. The final achieved biological effect relies on 
the delivery method, the used cell line, the target mRNA concentration and also 
siRNA sequence [16].  
 
 
1.2. Delivery of NAs 
Owning to reduced bioavailability in vivo, many promising drug candidates, 
including NAs, are not developed to their full potential. Thus, the need for the 
effective methods that enable the delivery of a therapeutic compound across the 
plasma membrane is urgent. A wide range of viral, chemical and physical 
delivery methods (Figure 1) may be used as platforms for the delivery of NAs. 
The delivery method or transport vector should be able to carry the NA mole-
cule to the target site, and also exhibit low toxicity and immunogenicity [17] 
and at the same time it has to maintain cargo activity, stability, be bio-
compatible, easy to produce, cost efficient, non-infectious and not causing 
adverse effects [3].  
 
 
1.2.1. Viral vectors 
Gene delivery systems are broadly divided into two groups: viral and non-viral 
vectors. Viral vectors harness viruses’ innate internalization mechanisms with 
minimized cytotoxicity. Adenoviral, adenovirus associated viruses (AAV), 
retroviral and lentiviral derived vectors are the most commonly used types of 
vectors [18˗20] and the newer generation viral vectors have been introduced to 
overcome the problems involving immunogenicity [21]. Several synthetic 
viruses featuring engineered components that are natural and synthetic [22] 
have been developed to obtain more controlled and predictable devices. Still, 
viruses’ innate properties may lead to the unwanted side-effects and to an 
increased risk of adverse effects caused by the vector. 
 
16 
 
Figure 1. Figurative representation of gene therapy and gene modification approaches 
and the methods that can be used for this application. CPPs – cell-penetrating peptides, 
LAD – laser assisted delivery. 
 
 
1.2.2. Non-viral delivery: physical and chemical methods 
The non-viral approaches consist of (modified) nucleic acids alone [23] or in 
conjunction with a carrier. Non-viral methods can be divided into physical 
methods and chemical vectors. They are considered less toxic and non-immu-
nogenic [24]. At the same time their use is limited due to their low gene transfer 
efficiency and in some cases in vivo instability and transient gene expression 
[25, 26]. The limitations of a non-viral delivery method may include the prema-
ture release of the cargo, degradation by the enzymes in the extracellular matrix 
and in the cells. The main limiting step is the internalization into the cells 
following entrapment in the endosomal compartments that leads to cargo’s deg-
radation in the Lys. 
Physical methods involve using a physical force such as electric field or 
physical contact with cell membrane in order to enable the internalization of 
NAs into the cell. Electroporation is commonly used for cultured cells, but 
results in high losses of cell viability. Microinjection refers to using a small 
needle to directly inject the NA material into the cell or the cell nucleus. This 
method is efficient, but time consuming and needs high accuracy and compe-
tence. Physical methods include also the use of gene guns, hydrodynamic injec-
tions, etc. The main limitation for the use of physical methods is the low 
applicability for systemic delivery in vivo.  
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Chemical methods include the use of a chemical compound or a trans-
porting molecule, which facilitates the delivery of NAs across the membranes 
of the cell. These vectors may be robust or finely tuned transporters and 
enhanced vectors may feature engineered components that are natural or syn-
thetic [22]. The advantages of chemical vectors, such as cationic lipids and 
cationic polymers, include the ease of production and the ability to deliver 
higher molecular weight NAs [26]. The main disadvantage of chemical vectors 
is the low transfection efficiency [27]. This may be caused by the negatively 
charged NA cargo that has to be delivered across membranes also carrying a 
negative charge [28]. Therefore the carrier must be able to shield the negative 
charges in the NA backbone and at the same time maintain the ability to deliver 
the cargo into the cell. 
 
 
1.3. Cell-penetrating peptides 
One of the promising non-viral delivery vectors are peptide sequences con-
sisting of ~5˗30 aa-s that are able to internalize into the cells. They are called 
CPPs, protein-transduction domains, membrane translocating peptides or Trojan 
peptides. First proteins that were able to cross membranes were discovered in 
1980s [29]. Firstly the protein-transduction domain of the trans-activator of 
transcription protein, Tat, was described by a group studying the human immu-
nodeficiency virus (HIV) [30, 31]. Secondly, penetratin, a CPP derived from the 
drosophila homeobox protein (antennapedia, Antp) was described shortly after 
[32, 33].  
Since then, hundreds of different CPPs have been developed with a com-
mon denominator that they can gain entry into the cells and can be used to 
facilitate the entry of proteins, small molecules, synthetic drugs, NAs, etc. 
linked to them [34] into various cells [35], usually with limited cell specificity. 
The CPPs are broadly classified into cationic or amphipathic CPPs. First dis-
covered CPPs were highly cationic [36], but later several peptides that were 
with lower net charge and higher hydrophobicity were discovered [37]. 
Although many naturally derived sequences were identified, a number of chi-
meric (transportan), synthetically designed (polyarginines) [38, 39] or modified 
peptides (PepFect) have also been generated to improve the cellular uptake and 
to provide higher cell/tissue specificity. Another way to classify CPPs is based 
on their origin and dividing them into natural protein derived, chimeric and 
synthetic sequences. 
The ability of the CPPs to deliver large cargoes to the intracellular envi-
ronment without decreasing the functionality of the cargo provides an oppor-
tunity to transport biologically active molecules. CPPs provide a platform for 
the development of medical treatments using molecules that were considered 
improbable for therapeutic application. The cargo can be attached to the CPPs 
covalently or by using non-covalent complexation strategy [40, 41]. In covalent 
bonding the number of cargo molecules per peptide can be controlled resulting 
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in a defined structure [42, 43]. Non-covalent strategy is more versatile, easier to 
perform and driven mainly on electrostatic interactions between the CPP and 
the cargo. Cationic CPPs can pack NAs into nanoparticles, protect the NAs 
from degradation [44], and mediate the cargos internalization into the cells, the 
release from endosomes and the transport to the target organelles.  
 
 
1.3.1. Transportan, PepFect, NickFect 
Transportan is a chimeric CPP, consisting of 27 aa-s. Its N-terminal sequence is 
derived from the neuropeptide galanin and C-terminal sequence is derived from 
a peptide toxin from wasp venom ˗ mastoparan. These two sequences are linked 
via an aa lysine (K) [45]. Transportan 10 (TP10) is a shortened version of 
transportan. In the TP10 the six first N-terminal aa-s of a peptide are removed, 
resulting in a less toxic CPP that harnesses the endocytotic pathways for gaining 
entry to the cells [46, 47]. N-terminally stearylated TP10 was named PepFect3 
(PF3) and has been used to deliver ONs and pDNA [48]. The modifications of 
PF3 have led to the development of the new efficient CPPs, PepFects (PF) and 
NickFects (NF). PepFect6 (PF6) was further enhanced by covalent attachment 
of trifluoromethylquinoline-based moieties (CQ) via a lysine tree in the K7 
position [49]. PepFect14 (PF14) was designed by replacing the K and 
isoleucines (I) by ornithines (O) and leucines (L) [50]. In NickFect1 I8 was 
replaced with threonine and tyrosine (Y) with phosphorylated analog [51].  
 
 
1.4. Characterization of CPPs and CPP/cargo complexes 
Over the past decades, numerous types of nanoparticles have been developed 
for medical and biotechnological applications. However, only a few are actually 
available on the market. One reason for this is the lack of understanding of the 
CPP/cargo complexes and their behavior upon contact with biological fluids 
and/or cell membranes. The complexes formed with the CPPs can be assessed 
on the basis of complex formation efficiency and the biological activity gained 
from the cargo. More importantly, the ability of the CPPs to protect the cargo 
from degradation and the possibility of CPP-cell interactions should be con-
sidered. For characterization of the CPP/cargo complexes various methods have 
been used, including intercalation of fluorescent dyes into pre-formed com-
plexes, transmission electron microscopy (TEM), dynamic light scattering 
(DLS), etc. All these methods have some advantages, but also disadvantages. 
Therefore, several methods should be used simultaneously in order to determine 
the parameters a CPP should have in order to work as an efficient delivery 
vector. Easiest and the most efficient way to assess the CPPs and the complexes 
formed between CPPs and the cargos is to use cell free and in vitro assays, 
where experimental conditions can be controlled more than in complex systems, 
such as mouse models. 
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1.4.1. The net charge and structure of the CPPs 
CPPs vary in the molecular weight, size and structure. The synthesis can be 
continued from the aa-s side chain [52] generating a branched or cyclic CPP 
instead of the linear peptide. The molecular weight varies from approximately 
thousand Da for short peptides to several kDa for longer, modified peptides. 
The secondary structure of a CPP, including random coils, α-helices or β-sheets, 
facilitates the interactions between the CPP and the cell membrane [53,54]. For 
some CPPs, the secondary structure is already formed in the free peptide. In 
others, they are induced when the peptide is interacting with the cargo or with a 
membrane. Although the most efficient CPPs have some similar features, no 
clear rules regarding the secondary structure can be proposed [55˗57].  
The charge distribution in the peptide sequence may play a role in the com-
plex formation and the interactions with the cell membranes for some CPPs. As 
a different example, the aa residues introduced into the original sequence of Tat 
peptide failed to influence cellular uptake, indicating that the cationic charge 
alone is needed for translocation [58]. The structural properties of the CPP as 
well as the outer layer of a CPP/cargo complex can facilitate the interaction 
with membrane components. For Tat peptide uptake, the role of cell membrane 
glycosaminoglycans has been shown [58]. For negatively charged particles 
formed from PF14 and ONs, the involvement of SCARA receptors has been 
shown [59]. Since no clear consensus has been reached which membrane ele-
ments are involved [60, 61], several have been proposed. For example, in addi-
tion to glycosaminoglycans and SCARAs, cationic peptides are shown to inter-
act with heparan sulfate proteoglycans [62].  
 
 
1.4.2. The size, surface charge and dissociation of the complexes 
The plasma membrane of the cell plays a crucial role in the selective permea-
bility, intracellular osmotic balance maintenance, compartmentalization, and 
cellular uptake [63]. Small molecules such as aa-s, ions, etc. are able to per-
meate cells through carriers and channels on the membrane. Macromolecules, 
such as proteins, DNA, RNA have to rely on other modes of entry. Nano-
particles are identified as having dimensions ≤ 100 nm, but larger sized particles 
may be needed to contain sufficient amount of the drug [64]. The transport of 
the smallest cargo to even large 120 kDa can be mediated by CPPs [65] both in 
vitro and in vivo. Depending on the CPP concentration and the size of the cargo, 
CPP/NA nanoparticle size may vary. Nanoparticles may or may not exhibit 
size-related properties that differ significantly from those observed in fine parti-
cles or bulk materials [66], but even small differences in the size may influence 
the actual distribution and thus bioavailability of the complex [67˗69]. How-
ever, not all particles with the same size behave similarly; therefore com-
position of the particle is important as well.  
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The nanoparticle surface charge may also affect the fate of the complexes in 
the cells. Membrane potential was shown to have a huge role in the inter-
nalization of arginine (R) rich CPPs [70˗72]. Because of the surface charge, 
CPP/cargo complexes may interact with the serum components, leading to a 
change in stability and/or lead to the formulation of aggregates. One way to 
modify the surface of the complexes and to improve the half-life of the peptide 
is the addition of polyethylenglycol (PEG) to the peptide sequence. Surface 
functionalization of gold nanoparticles with PEG has been used and resulted in 
efficient internalization and localization in the nuclear region [73]. Nano-
complexes consisting of the CPPs, poly(lactic-co-glycolic acid) (PLGA) and 
cargo have been used to improve doxorubicin delivery or drug delivery to the 
brain [74,75]. At the same time, masking the charges or modifying the 
nanoparticles may not improve the delivery as the CPP charge plays a role in 
the interactions with the cell surface components, such as receptors [76].  
CPPs are a target for degradation by proteases. This degradation is an 
advantage, but also a disadvantage for the peptide-based delivery systems. The 
advantage comes from the ability of the cells to degrade the delivery agent, so 
no permanent damage or toxic effects remain. The disadvantage of being a 
target for proteases is that it may lead to the premature degradation of the CPP 
and the dissociation of the complexes. Several strategies have been used to 
increase the stability of the peptides, including the use on aa-s generally not 
included in the protein sequences, so they would not be as easily recognized by 
the enzymes [50]. At the same time the dissociation of the complexes at the 
target site is needed to release the cargo and gain desired biological effect. The 
CPPs that pack NAs into nanocomplexes without dissociation in the presence of 
serum show promise for use in non-covalent complexation strategy [77]. 
 
  
1.5. Internalization and trafficking of the cargo and 
the complexes 
The mechanisms by which CPPs promote uptake of the associated molecules 
are influenced by the physico-chemical properties of the CPPs, the molecular 
cargo, and the variety of cells and tissues being treated. Two general models of 
CPP uptake have been proposed: energy-independent direct translocation across 
the plasma membrane to the cytosolic compartment [78, 79] and endocytosis 
[80˗82]. Several internalization pathways, including caveolar, clathrin-mediated 
endocytosis and macropinocytosis, have been demonstrated for different CPPs 
[83, 84]. Results from studies conducted thus far suggest that the mechanism of 
uptake is highly dependent on the type of cargo, making it difficult to predict 
which penetrating peptide should be selected in each case [85˗87]. In the case of 
endocytosis, the fate of the CPP-cargo complexes depends on their ability to 
escape the endosomal compartments before being delivered to the Lys for deg-
radation. Endocytotic mechanism of cellular delivery can limit the effectiveness 
of the CPP-based deliveries by decreasing the amount of cargo that is active and 
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able to reach the target. Strategies for increasing endosomolysis, thereby 
making more active cargo available, involve the use of pH-responsive elements, 
which are active in the acidic environment of the endosomes without disrupting 
the membranes of other organelles [49, 88]. Examples include the addition of a 
short peptide derivative of the influenza virus protein hemagglutinin or the use 
of a synthetically designed peptide, GALA [89].  
 
 
1.5.1. Endocytosis 
The mechanisms of cellular uptake of the CPPs and the CPP/cargo complexes 
have been discussed extensively in several reviews [37, 85, 90]. In addition, 
CPPsite [91], an online database of CPPs, describes the almost 2000 known 
CPPs and provides information about uptake mechanisms for each peptide. 
Still, the exact internalization mechanism is not known and the probable reason 
behind these inconsistencies may lay in the diversity of the CPPs, used con-
centration, properties of the cargo (size, charge), temperature, proteins in the 
media, interactions with cell membrane and the state of the cells [92, 93]. In 
addition, the same CPP can harness more than one pathway, if needed [80].  
The internalization of particles occurs after interactions with the cell mem-
brane [94] and the two most likely pathways involve the direct penetration via 
the formation of an inverted micelle, membrane thinning, carpet-like model or 
of pore formation [32,95˗97] or use of the endocytotic pathways. When attached 
to a cargo, the CPP/cargo complexes use mainly endocytosis to gain access to 
the cell interior. Endocytosis is a universal process occurring in the cells with 
the aim of gaining material from the cell exterior into the cell [98]. In addition 
to this, endocytotic pathways enable the sorting and transport of different 
products into the cell. Endocytosis is classically divided into different pathways, 
involving phagocytosis and pinocytosis. Pinocytosis is in addition divided into 
macropinocytosis, caveolin- and clathrin dependent endocytosis and caveolin 
and clathrin independent endocytosis [99] (Figure 2). Receptors in the receptor-
mediated endocytosis assure the selectivity and cytosolic adaptor proteins 
assure the right sorting of endocytosed material.  
Clathrin-coated pits and caveolae are two of the most recognizable features 
of the plasma membrane of the mammalian cells [100]. The importance of 
clathrin-mediated endocytotic (CME) pathway in uptake, trafficking, recycling, 
and degradation of the internalized compartments has been extensively studied 
[101] and clathrin controls several physiological functions, including synaptic 
vesicle internalization in neurons [102]. The CME involves the budding of 
clathrin coated plasma membrane inner layer to internalize receptor bound 
material. Following budding, the vesicle is uncoated and delivered to early 
endosomes (EE). Caveola/lipid raft-mediated, clathrin-independent endocytosis 
has emerged as another crucial trafficking pathway [103]. Caveolae and lipid 
rafts (membrane domains enriched in cholesterol and glycosphingolipids) parti-
cipate in many cellular events, including cholesterol trafficking and inter-
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nalization of certain toxins, viruses, GPI-anchored (glycosylphosphatidylinositol-
anchored) proteins, and many other cargos [104, 105]. Caveolae are flask-
shaped invaginations in the plasma membrane that co-localize with cholesterol 
and sphingolipid-rich membrane domains containing signaling molecules and 
membrane transporters. Caveolin is the driving dimeric protein behind the 
caveolae formation. After binding to the cholesterol it causes the inner surface 
membrane invaginations. Macropinocytosis is regarded as a nonspecific inter-
nalization route, because it is generally not mediated by receptors. Macro-
pinocytosis involves the ruffling of the membrane and formation of la-
mellapodia. These structures are cell membrane protrusions and after collapsing 
into macropinosomes engulf large amount of the extracellular material. 
Following internalization, the formed vesicles are routed to transport vesicles – 
endosomes.  
 
 
1.5.2. Endosomal trafficking of internalized particles 
Endosomes are endocytotic vesicles and they are a part of a trafficking system 
in the cell. This system is responsible for the delivery of endocytosed material 
to the right cellular compartments. Each subtype of vesicles is characterized by 
distinct proteins and the transport is coordinated by Rab-GTPases [106]. For 
caveolin and clathrin dependent endocytosis, the vesicles are routed to EEs, a 
checkpoint and initial sorting depot [107]. From there the endocytosed material 
is re-routed to the cell membrane (exocytosis) or to the late endosomes (LE). 
Sorting initiated in the EEs predetermines the course for internalized material, 
prioritizing it for recycling, exocytosis, degradation in Lys or delivery to trans-
Golgi network. During the maturation of an endosome (Figure 2) a set of 
vacuolar ATPases in the vesicle membrane change their activity and pH drops 
from 7.4 to pH 5 in mature Lys. In the EEs, the pH is slightly acidic compared 
to the extracellular environment and EEs can be recognized by the presence of 
Rab5 proteins in the membrane. From EEs the material is transferred to the LEs 
or the EEs are matured into LEs by the change of membrane proteins and the 
decrease of pH. LEs contain hydrolytically active lysosomal hydrolases and the 
first steps of degradation start in LEs. The low pH and activation of degradation 
enzymes by the pH enables the final lysis of content in the Lys [108]. The 
extended stay of nanoparticles in the endosomal compartments may lead to their 
degradation [94] and therefore the endosomal escape is needed in order to reach 
the target site intactly. Entrapment in endosomes is one of the major limitations 
for a non-viral delivery vector mediated transport [109]. After endosomal 
escape the nanoparticle has to reach the target in the cytosol or organelle and 
release the cargo. This is needed for the cargo to take its intended action.  
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Figure 2. Schematic illustration of the main endocytotic pathways and intracellular 
routing of endocytosed nanoparticles with siRNA and pDNA. Endocytic pathways: 
1. Macropinocytosis, 2. Clathrin- and caveolin-independent endocytosis, 3. Caveolin-
mediated endocytosis, 4. Clathrin-dependent endocytosis. Endosomal vesicles: EE – 
early endosomes. LE – late endosomes, Lys – lysosomes. RNAi – RNA interference, 
NA – nucleic acid, CPP – cell-penetrating peptide, SCO – splice correction oligo-
nucleotide, pDNA – plasmid DNA. 
Delivery to the nucleus
and gene expression from 
pDNA or splice correction 
mediated by SCO
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2. AIMS OF THE STUDY 
The ability of CPPs to cross membranes and facilitate the uptake of various 
cargoes attached to the CPP has been widely recognized. Still, there are several 
limitations that restrict the use of the CPPs for the delivery of cargo in in vivo 
applicatios. The final biological effect gained from the delivered cargo relies on 
several aspects, including the interactions between the CPP and the cargo, the 
efficiency of nanoparticle formation, nanoparticle stability, and the interactions 
of the CPPs or the complexes with the cell membrane and intracellular 
trafficking of the internalized CPP/cargo particles. The in vitro testing of the 
CPPs and the characterization of the CPP/cargo particles provide data for their 
application in vitro and basis which further in vivo steps rely on.  
 
More precisely, the aims of the study were: 
Paper I: to evaluate the impact of two different modifications in the CPP 
sequence to the CPP/NA complex formation and the delivery of 
NAs. Test the applicability of the most efficient analogue for the 
delivery of pDNA in different cell lines and for protein production 
technology. 
Paper II: to characterize the internalization and the intracellular trafficking of 
pDNA mediated by delivery vectors NF1 and NF51. Assess the role 
of the modifications in the peptide sequence on the internalization 
efficiency, internalization route and intracellular trafficking. 
Paper III: to validate two methods that can be used for the tracking of the 
CPP/pDNA complexes after internalization and their endosomal 
release. Assess the influence of the modifications in the NF1 and 
NF51 on the intracellular trafficking of the cargo and endosomal 
release of the complexes. 
Paper IV: to determine the binding properties of NFs and PFs to siRNAs, the 
CPP/siRNA complex structure and their stability to enzymatic deg-
radation. Determine the physical and chemical properties of the 
formed CPP/siRNA complexes in order to obtain a model of com-
plex formation between the most efficient tested CPP and siRNA. 
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3. METHODOLOGICAL CONCIDERATIONS 
The methods used in this study are described comprehensively in the respective 
papers and only brief comments on the chosen methods are given here. 
The in vitro models provide an opportunity to study the cellular response 
and the CPP/cargo properties in a closed and simplified system. Such models 
provide preliminary information about the complexes and provide alternative 
means for drug and chemical testing up to some levels. Advantages associated 
with the in vitro methods are time efficiency and cost effectiveness. 
 
 
3.1. Peptides 
In the current thesis the CPPs derived from TP10 were used (Table 1). Previous 
studies have shown an improved transfection efficiency of the CPPs when a  
N-terminal stearic acid was added. All tested peptides are considered as further 
modifications of PepFect3 (stearyl-TP10, PF3) and were synthesized by using a 
solid-phase peptide synthesis strategy (SPPS). In SPPS the first aa of the pep-
tide is linked to a solid polymer, e.g. resin, and the synthesis is carried out in a 
stepwise manner. The advantage of using the SPPS is that it does not need puri-
fication between the aa coupling and deprotection. This synthesis strategy offers 
a versatile method to introduce modifications into the peptide sequence at any 
given step of the synthesis and without drastically changing the protocol. Pre-
requestite for this is the use of an aa with the suitable protection groups. Two 
main strategies regarding the protection of side chain amino groups are used in 
the SPPS. First uses 9-fluorenylmethyloxycarbonyl (Fmoc) and second uses 
tert-butyloxycarbonyl (t-Boc). The main difference arises from the needed con-
ditions for the removal of Fmoc and t-Boc. Fmoc is removed by a strong base 
and t-Boc can be removed by a strong acid. The side chain groups of aa-s are 
protected with protection groups that are removed during the final peptide 
cleavage from the solid support, not during the synthesis. After cleavage from 
the resin and the final deprotection of aa side chain groups, the peptides were 
purified with reverse-phase high-performance liquid chromatography (RP-HPLC) 
and the correct product-containing fractions were identified by MALDI-TOF 
(matrix-assisted laser desorption-ionization time-of-flight) mass spectrometry.  
In paper I the peptide sequence of stearyl-TP10 was modified by in-
troducing O7 instead of K7 in the sequence and/or continuing the synthesis 
from the aa side chain, instead of α-amino group. These modifications were 
used to increase the serum stability of the CPP and also to create a flexible 
kinked structure in the peptide. 
Papers II and III describe the CPP/pDNA complex formation, stability and 
intracellular trafficking of formed nanoparticles. Paper II focuses on thorough 
characterization of NF/pDNA complexes, their internalization and intracellular 
delivery. Paper III describes two methods that can be used to determine the 
endosomal transport and the release of complexes from the endosomes and how 
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the endosomal localization differs between the pDNA delivered by these CPPs. 
NF1 and NF51 are new CPPs that were previously used for the delivery of dif-
ferent NA cargoes [51,paper I]. From each set of designed CPPs, these two 
were the most efficient. We used NF1 and NF51 to deliver pDNA into HeLa 
cells and to determine the properties and cellular events involved with their high 
efficiency.  
In paper IV the binding of CPPs to siRNA and complex formation were 
investigated. Five analogues of TP10 were compared (PF3, PF6, PF14, NF51, 
NF57) on the basis of complex formation, stability and ability to deliver siRNA 
into the cells and mediate downregulation of a target gene. These CPPs were 
chosen because of their previously shown efficiency in delivering siRNA. 
 
Table 1. CPPs used in this thesis. 
Name Sequence Paper Reference 
Transportan10, TP10 AGYLLGKINLKALAALAKKIL-NH2 IV [47] 
PepFect3, PF3 Stearyl-AGYLLGKINLKALAALAKKIL-NH2 
IV [48] 
PepFect6, PF6 Stearyl-AGYLLGK*INLKALAALAKKIL-NH2 
IV [49]  
PepFect14, PF14 Stearyl-AGYLLGKLLOOLAAAALOOLL-NH2 
IV [50] 
NickFect1, NF1 Streayl-AGY*LLGKTNLKALAALAKKIL-NH2
I, II, 
III [51] 
NickFect51, NF51 (Stearyl-AGYLLG)δOINLKALAALAKKIL-NH2 
I, II, 
III, 
IV 
Paper I 
NickFect53, NF53 (Stearyl-AGYLLG)εKINLKALAALAKKIL-NH2 I Paper I 
NickFect61, NF61 Stearyl-AGYLLGOINLKALAALAKKIL-NH2 
I Paper I 
NickFect57, NF57 (Stearyl-AGYLLG)δOINLKALAALAKAIL-NH2 IV Paper IV 
K*  *QN  
Y* Tyrosine with phosphoryl group 
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3.2. Non-covalent complex formation and 
nanoparticle characterization 
There are two main strategies used to associate the cargo with the CPP. These 
are covalent conjugation and non-covalent complex formation. The non-covalent 
strategy was first utilized by G. Divita´s group [110] and relies on electrostatic 
interactions between the positively charged aa-s in the peptide sequence and the 
negatively charged phosphate backbone of the nucleic acid molecule. The first 
step of nanoparticle formation is the interaction of a CPP with a cargo. In order 
to have a stable complex a positively charged tripeptide may not be enough 
[111]. Hydrophobic and hydrophilic interactions and/or interactions with other 
aa-s in the sequence may be needed to stabilize the complex. The N-terminal 
fatty acid and positively charged aa-s in the C-terminal part enable to create two 
distinct regions in the same peptide sequence. Both hydrophobic and hydro-
philic faces of amphiphilic peptides are likely involved in the interactions with 
RNAs [112]. Different methods have been used to describe CPP and cargo 
complexes and their formation. In this thesis gel electrophoresis, isothermal 
calorimetry, florescent dye intercalation assay and ethidium bromide quenching 
assay were used to characterize the complex formation between CPPs and 
nucleic acid cargoes. 
 
 
3.2.1. Isothermal calorimetry 
Stability of the formed nanoparticle determines the CPP/cargo complex disso-
ciation at the target site. Isothermal calorimetry (iTC) is a highly accurate and 
sensitive method for simultaneous determination of KA [M-1], stoichiometry and 
thermodynamic parameters (ΔG, ΔH, and ΔS) in a simplified experimental set-
up compared to in vivo experiments. The formation of siRNA and CPP complex 
is an exothermic process resulting in the release of heat. A cell containing a 
constant volume of siRNA is titrated with a series of additions of CPP mole-
cules. When binding reaches saturation, fewer complexes are generated, there-
fore less heat is released. Although high picomolar Kd values have been 
reported using iTC, measurements in the 10−8 to 10−9 M−1 range are more 
common. Although iTC can work at lower sample concentrations, any concen-
trations lower than high nM is not sufficient. If a high nM sample concentration 
is chosen with a low picomolar Kd binding system, the titration curve is too 
steep, giving rise to a significant error in Kd. This limitation of iTC could be 
important, because complex formation is dependent on CPP and cargo concen-
trations, therefore results obtained by standard complex formation protocol and 
concentrations could be more relevant.  
In paper IV iTC was used to determine the binding affinities of siRNA and 
CPP at biologically relevant pH-s and with CPPs differing in net charge, size 
and modifications. 
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3.2.2. Model calculations 
Model calculations are based on the sequence of the CPP. The advantage of 
using modeling instead of experiment is that it improves the understanding of 
the system and permits exploration of alternatives without the need of syn-
thesizing and going through a set of experiments for each peptide. The calcu-
lations are based on physical and chemical properties of each link in the peptide 
sequence. One of the ways to use mathematical models is to determine the net 
charge of the peptide at various biologically relevant pH-s. When exposed to the 
media and entering the cell, the particle is exposed to a pH drop in endosomes 
and increase after release from endosomes to the cytosol. This pH change may 
affect the stability of the complex. The mathematical calculation of net charge 
enables to assess the change of charge of the CPP during the delivery when 
exposed to intracellular and extracellular pH. For each cargo, there should be an 
optimal number of positive charges in the peptide sequence that interact with it 
to form the nanoparticle. Hydrophobicity, more specifically the regions in the 
peptide that are hydrophilic and hydrophobic and how they are located in the 
higher structures can also be estimated by mathematical modeling. Experi-
mental setup for determining these parameters are time consuming and the con-
ditions may alter the result.  
In paper I, II and III the charge ratio (CR) was used to express the ratio of 
CPP over pDNA in complex formation solution. Charge ratio is based on the 
theoretical number of negative charges in the plasmid backbone, positively 
charged aa-s in the peptide sequence and their ratio to each other. The net 
charge of peptides and conversion from CR to molar ratio is shown in table 2. 
In paper I and IV the molar ratios were used to express the excess of peptide 
over siRNA or SCO. This is based on the amount of moles of CPP and cargo. 
Molar ratios are widely used to express CPP/siRNA nanocomplex formation 
ratios, but can be expressed in charge ratios also (Table 2). 
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3.2.3. Gel electrophoresis 
Gel electrophoresis enables to assess the complex formation between CPPs and 
cargoes. The mobility in gel during electrophoresis depends on the molecules 
charge, size and shape. In nucleic acid bound to the CPPs the negative charges 
are neutralized by positive charges of the peptide. In addition to that, the 
movement of CPP/cargo complex is limited in the agarose gel network. The 
complex formation is assessed by the detection of nucleic acid band after elec-
trophoresis. In case of pDNA, more than one band for one plasmid can be 
detected, because the plasmid can be in circular or supercoiled form and 
depending on that move in the gel faster or slower. In the case of siRNA, there 
is usually only one detectable band. 
Gel electrophoresis on pre-formed complexes is a common method widely 
used for screening the CPP/cargo complex formation (used in paper II, III, IV). 
In paper IV gel electrophoresis was used to assess the complex formation of 
CPP/siRNA complexes at different pH conditions. For this, complexes were 
formed in different buffers, incubated at room temperature, mixed with loading 
dye and transferred to gel teeth. 
 
 
3.2.4. Fluorescent dye intercalation assay  
for nanoparticle characterization 
Fluorescent dyes that specifically bind to the nucleic acids can be used to assess 
the accessible cargo in the complexes and also the complex formation and the 
release of the cargo. Ethidium bromide is commonly used for that purpose, but 
today several other dyes have been developed. PicoGreen is a fluorescent dye 
that maintains its fluorescence intensity even after longer periods of excitation 
and can be used for prolonged measurements. It intercalates into the minor 
groove [113] of double stranded nucleic acid when NA is accessible.  
In paper II and IV fluorescent NA binding dyes were used to assess the 
complex resistance to heparin displacement. The interaction between the CPP 
and the cargo has to be optimal in order to maintain stability during the delivery 
and also to enable the release of cargo at the target site. Heparin sodium salt is a 
molecule with high negative charge density and is able to replace the nucleic 
acid cargo in the loosely packed complex. The critical concentration at which 
50% of nucleic acid is replaced in the complex enables to compare the stability 
of complexes. After complexes were formed, heparin solution at different con-
centrations was added and complexes incubated further. After incubation, a dye 
was added to detect the plasmid that had been replaced by heparin and therefore 
available for dye binding. 
During delivery the complexes have to be stable to enzymatic degradation. 
The complexes consist of nucleic acid and peptides. Nucleases and proteases 
are two types of enzymes responsible for degrading protein/peptide and NA 
molecules in the cells and tissues. Proteinase K and RNase A were used to to 
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assess the complex resistance to enzymatic degradation and to pinpoint the 
component in the complex that causes the low stability. 
In paper IV fluorescent dye intercalation was used both to assess the com-
plex formation, and the resistances enzymatic degradation. For complex for-
mation a fluorescent dye was added to the complex solution after incubation at 
room temperature and the percent of accessible siRNA was calculated based on 
the fluorescence intensities. For enzymatic degradation assay a fluorescent dye 
was added to pre-formed complexes to determine the initial percentage of 
accessible siRNA. Thereafter the enzymes Proteinase K or RNase A were added 
and incubated, following the measurement of changes in fluorescence inten-
sities over the period of 24 h. 
 
 
3.2.5. Dynamic light scattering and zeta potential 
Dynamic light scattering (DLS) is a spectroscopic method that enables to 
determine the hydrodynamic mean size of formed complexes in solution. Nano-
particles in solution may be regarded as a part of colloidal dispersion system, 
where molecules follow the random Brownian motion, which causes the laser 
light to be scattered at different intensities. The time-dependent fluctuations are 
directly related to the rate of diffusion of the molecule through the solvent, 
which is related to the hydrodynamic diameter. The zeta potential correlates 
with the surface charge of the nanoparticles in a solution. Particle size and zeta 
potential are important parameters of a nanoparticle and may influence the 
internalization, stability and biodistribution of the complexes. 
In paper I and II DLS was used to determine the size and zeta potential of 
complexes in MQ water and also in the presence of media and serum. In paper 
III DLS was used to determine whether the complexes formed with Cy-5 
labeled pDNA differ significantly in the nanoparticle size. 
 
 
3.3. Cell cultures 
Experiments on cell cultures are alternative and also a crucial step before in vivo 
testing. Cell cultures are routinely used for preliminary screening of potential 
drug molecules/chemicals to test their efficacy. NA transfection with NFs and 
PFs was tested in several cell lines (Table 3), out of which CHO, HeLa and 
HEK 293 cell lines are widely used in cell biology research and biotechnology. 
They are easy to handle and are commonly used in drug delivery studies. MEF, 
Jurkat and A20 cells are considered hard-to transfect cells and were used to test 
if it is possible to efficiently deliver pDNA with NF51 into these cells. U87 
cells are cancer cells and were used to compare the potential of NFs and PFs as 
siRNA delivery vechicles. U2OS and U87 were used to test NF51 ability to 
deliver pDNA into cancer cells. 
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Table 3. Cell lines used in this thesis 
Cell line  Cell type Paper 
CHO (CHO-K1; EGFP-CHO; 
CHOEBNALT85) chinese hamster ovary cells I 
MEF mouse embryonic fibroblasts I 
HeLa (HeLa; HeLa pLuc705) human cervical carcinoma cells I, II, III 
HEK 293 human embryonic kidney cells I, III 
U2OS (U2OS; 
U2OSSEBNALTD3) human osteosarcoma cells I 
U87 (U87; U87-luc2) human glioblastoma-astrocytoma cells I, IV 
Jurkat human T lymphocyte cells I 
A20 mouse B lymphoma cells I 
 
 
3.4. Transfection experiments 
The plasmid delivery efficiency of CPPs was determined by using a reporter 
system based on luciferase (luc) encoding pGL3 plasmid. This luciferin-
luciferase system is sensitive, reproducible and easy to measure.  
Plasmids are large molecules compared to other cargoes delivered by CPPs. 
The size varies from 4 kb for minicircles to tens of thousands base pairs for 
double reporter plasmids. In paper I, II and III the efficiency of CPPs was 
evaluated by transfecting cells with pGL3 (4.2 kbp or 5.2 kbp) reporter plasmid. 
Plasmid that is delivered to the nucleus can use the transcription and translation 
systems of the cell and the luc is expressed. To the cell lysate luciferase sub-
strate luciferin is added and luminescence is measured. The measured lumi-
nescence correlates with the amount of luc expressed in the cell.  
In paper I pQMCF-CMV-EGPF plasmid was delivered with NF51 into 
U2OSSEBNALTD3 and CHOEBNALT85 cells and number of transfected cells 
was measured with FACS (fluorescence assisted cell sorter) 24 h and 7 days 
post transfection, by detecting the EGPF. QMCF tehnology enables the expres-
sion of biologically active substances by generating expression cell banks 
within one week and production cell line for stable protein production in 6–8 
months. 
For gene downregulation in paper I and IV the cells that stably express luc 
or EGFP were used and siRNA targeting that gene product (mRNA) was de-
livered to the cytosol. SiRNA strand, when bound to its target, induces RNAi 
and the degradation of the target product, therefore no protein can be produced 
from this mRNA. In paper IV U87 cells encoding luc2 gene and in paper I CHO 
cells expressing EGFP gene gene were treated with CPP/siRNA. The efficiency 
of downregulation was measured by the percent of remaining luc2 or EGFP 
activity.  
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In paper I HeLa pLuc705 cells expressing non-functional luc gene were 
treated with CPP/SCO complexes delivering the SCO to modulate non-func-
tional luc gene splicing. The efficiency of splice correction was expressed by 
the fold increase of luc gene activity after transfection.  
As negative and positive controls cells treated with MQ water and the 
commercial reagent RNAiMAX or LF2000 were used. 
 
 
3.5. Cellular uptake and intracellular trafficking 
of nanoparticles 
There are several methods that are used to track the internalization and traf-
ficking of nanoparticles. Most commonly different chemical inhibitors are used 
to block the pathways mediated by receptors. Chemical inhibitors directly bind 
to the receptor or disrupt their synthesis or presentation of these receptors on the 
cell membrane. The energy dependent endocytosis can be blocked by low tem-
perature or by depletion of the cellular pool of ATP. This enables to differen-
tiate energy dependent endocytosis from energy independent pathways i.e. 
direct translocation.  
 
 
3.5.1. Membrane interactions – lactate dehydrogenase leakage 
Lactate dehydrogenase (LDH) is an enzyme present in all living cells and cata-
lyzes the reversible transformation of pyruvate to lactate under anaerobic con-
ditions, coupled with the oxidation of NADH to NAD+. Each normal tissue has 
a distinct LDH activity pattern, depending on their functions and levels of LDH 
increase in response decreased cell integrity in tissue injury. In cancer cells the 
LDH A levels are elevated and have been linked to tumor growth, maintenance 
and invasion [113]. The LDH A up regulation increases the efficiency of an-
aerobic glycolysis in tumor cells and reduces their dependency on oxygen. The 
release of LDH is commonly measured in order to test the cytotoxicity of com-
pounds. 
In paper IV U87 cells were used. U87 cell line has elevated levels of LDH 
and therefore an interaction between the CPP and the cell following a pore for-
mation and release of LDH can be detected more easily than with non-can-
cerous cell lines where LDH levels are commonly lower. 
 
 
3.5.2. Inhibition and downregulation of scavenger receptors 
Scavenger receptors are cell-surface receptors that bind with low specificity 
anionic ligands. Scavenger receptors are involved in the uptake of negatively 
charged particles and the involvement of SCARA receptors has been shown for 
PF14/cargo complexes interactions with cells [59]. 
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In paper II the role of SCARA in CPP/pDNA particle uptake was assessed 
by pre-treating cells with specific inhibitory ligands for SCARA: polyiosinic 
acid, dextran sulfate and fucoidan. Following the transfection of pDNA with 
CPPs, the effect was assessed by comparing the luciferase expression level in 
the cells treated with inhibitors and cells pre-treated with inhibitors. For 
SCARA downregulation SCARA3 and SCARA5 specific siRNAs were used. 
The cells were transfected with commercially available liposome based trans-
fection reagent RNAiMAX 24 h prior of adding CPP/pDNA complexes. 
Expression from plasmid was measured 24 h after treating with CPP/siRNA. 
 
 
3.5.3. Inhibition of endocytosis pathways 
In eukaryotic cells, endocytosis is an important cellular process to internalize 
various cargo molecules, to regulate signal transduction pathways and is the 
main way for a cell to internalize solutions and particles in the solution. A num-
ber of endocytic pathways have been demonstrated to be involved in the uptake 
of DNA complexes [115, 116] and this is highly dependent on the cell type 
[117], the nature of the gene carrier [118] and the particle size [119]. This vari-
ability stresses the need to study the internalization of each of the different type 
of CPPs as gene carriers in the appropriate cell line model. CPP/cargo com-
plexes are shown to use different endocytotic pathways by applying pharma-
cologic and molecular manipulations to selectively disrupt distinct endocytic 
pathways. In paper II chloropromazine, cytochalasine D, nystatin and chloro-
quine were used as pharmaceutical compounds to block certain pathways. Re-
garding their specificity, an increasing volume of evidence suggests that these 
inhibitors are not higly specific. Another drawback for using inhibitors is that 
nanocomplexes may use several internalization pathways simultaneously and 
blocking one pathway may cause the increased harnessing of another. In 
addition to this, off-target effects may occur due to the inhibitor. Therefore the 
results obtained by using inhibitors should be interpreted carefully.  
Chloropromazine is a cationic amphiphilic drug which is deemed to inhibit 
clathrin-coated pit formation by a reversible translocation of clathrin and its 
adapter proteins from the plasma membrane to intracellular vesicles. As a side 
effect, it may insert into plasma membrane and alter the membrane fluidity. In 
addition it may inhibit phospholipase C and by that alter macropinocytosis and 
actin dynamics. Cytochalasin D is a drug that prevents actin polymerization and 
leads to the disassembly of the existing actin, inhibiting membrane ruffling and 
micropinocytosis. In addition, it may also affect the clathrin- or caveolin-
mediated pathways. Nystatin is a polyene antifungal drug which binds to sterols, 
flattens caveolae and dissassembles the coat of clathrin-coated pits [120, 121]. 
Chloroquine (CQ) is an endosomolytic molecule and in its unprotonated 
form is able to cross membranes and accumulate in the acidic organelles of the 
cell. CQ is able to buffer the acidification of acidic organelles and its accu-
mulation in the same organelle may cause its rupture. Addition of CQ enables to 
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assess the endosomal release capability of complexes from the acidic organelles 
such as Lys and LEs. If there was a significant increase in the final biological 
effect gained form delivered cargo, most probably the entrapment of complexes 
in LE and Lys may be one of the main limiting factors for the CPP. CQ was 
used in paper I, II and III to assess the endosomal release of complexes, and 
also in paper III as one component in a three component (CQ, Bafilomycin A, 
Nocodazol) assay designed to elucidate the CPP´s mechanism of action in 
endocytotic pathway. Bafilomycin A is an inhibitor of vacuolar ATPases and 
inhibits the acidification of endosomes. In HeLa cells, it is also able to block the 
maturation of endosomes from EE to LE. To assess the role of endocytosis and 
acidification Nocodazol was also used in comparison to Bafilomycin A and CQ. 
Nocodazol is able to block the actin filament synthesis in the cells, cause disas-
sembly of microtubules and therefore block the endocytosis, without blocking 
the acidification of vesicles. 
 
 
3.5.4. Separation of endosomes 
Endosomes are membrane bound organelles in the cells, responsible for trans-
porting endocytosed material and trafficking of the molecules produced in the 
cell. There have been several methods that enable the tracking of the CPP/cargo 
complexes, but most of them require labeling of the cargo or the CPP. The 
labels may affect the pathway and physico-chemical properties of the com-
plexes; therefore a multi-step centrifugation offers an alternative to labeling and 
enables to assess the amount of cargo in certain organelles. Caused by different 
sediment velocities of organelles found in the cell, by choosing right density 
gradients and centrifugation forces, the organelles can be separated from each 
other. The drawbacks of using centrifugation methods, is the low repro-
ducibility of experiments caused by biological variety and multi-step prepa-
ration, high time consumption and loss of material during the purification steps. 
Using self-forming gradient solutions, such as Percoll, enables to increase re-
producibility and also decrease the hands-on time for the experiments. Still, 
centrifugation is used for the separation of cell populations from tissues, 
acquiring organells from the cells and separating and concentrating different 
types of organelles in a gradient. Determination of the complex location and 
change in quantity over time helps to understand the events during the delivery 
and contribute in CPP development or choosing the suitable application for the 
CPP. 
In paper II the differential centrifugation and fractionation on Percoll was 
used to assess the amount of pDNA in early endosomes and Lys for HeLa cells 
transfected with NF/pDNA. In paper III HeLa and HEK293 cells were used in 
comparison. Centrifugation and fractionation of transfected cells was used to 
determine the localization and quantity of pDNA after CPP-mediated delivery 
in endosomal vesicles without the need of labeling either. 
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3.5.5. Single particle tracking 
Single particle tracking (SPT) is a powerful tool to study the dynamics of intri-
cate systems such as the living cell. The single molecule techniques over the 
past two decades have changed the field of cell biology by providing a more 
quantitative picture of the complex and highly dynamic organization of living 
systems. Amongst these techniques, single particle tracking (SPT) is an 
approach to study a variety of dynamic processes. SPT locates each particle and 
measures its individual dynamics and exploits the fact that the location of an 
isolated particle can be measured to a high accuracy. SPT provides access to 
single molecule behavior in the natural context of living cells, thereby allowing 
a complete statistical characterization of the system under study. 
There have been several applications for SPT in the analysis of cell surface, 
viral infection of cells and processes in gene transcription. The advantage of 
SPT is the straightforward approach and imaging of live cells, whereas the 
cargo or organelles have to be fluorescently marked. To arrive at such single-
particle trajectories, particles first need to be located within the images and, 
secondly, these locations have to be connected to trajectories. 
In paper IV Cy5-pDNA was used and CPP without a label to form 
CPP/Cy5-pDNA complexes. Cells were pre-treated with BacMam reagent to 
have fluorescently labelled organelles (EE-Rab5; Lysosomes – LAMP1). Cells 
were treated with complexes only for a short period (15 min) to have optimal 
number for downstream SPT analysis. The co-localization events of labeled 
pDNA and EE or Lys were measured to elucidate the intracellular trafficking of 
CPP/pDNA complexes. 
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4. RESULTS AND DISCUSSION 
In the papers included in this thesis, the aim was to investigate the selected 
CPPs on the basis of NA delivery efficiency and to link this to the CPP/cargo 
complex formation efficacy and the physicochemical properties of the com-
plexes. Although derived from similar backgrounds, the modifications in the 
peptide sequences have led to differences in complex stabilities, internalization 
pathways and also to intracellular fate. 
In paper I the novel stearyl-TP10 analogues belonging to the NF family 
were introduced for NA delivery. In paper II and III the NF/pDNA complexes 
were characterized, their internalization pathway determined and intracellular 
trafficking described. In addition, in paper III two methods of tracking the 
intacellular trafficking of CPP/pDNA were compared. In paper IV, the complex 
formation between NFs or PFs and siRNA was thoroughly described and a 
model of complex formation proposed. In this chapter, the results obtained from 
each paper will be summarized and discussed. 
 
 
4.1. NickFect51 for the delivery of NAs and application 
in protein production (Paper I) 
Modification of the CPP sequence is a way to improve their stability, chemical 
or physical properties. The sequence of stearyl-TP10 was modified to increase 
the CPP-mediated NA transfection efficiency. For this, two different modi-
fications were tested. Firstly, to improve the serum stability of the CPP, O was 
introduced into the sequence. The use of O instead of K should increase the 
stability of the peptide [50], as O is naturally not included in the protein 
sequences and is less likely to be recognized by the proteases. The second 
modification was introduced to increase the flexibility and peptide bond sta-
bility [52] of the aa7. Both modifications were introduced separately, resulting 
in NF61 and NF53, or in combination, resulting in the CPP NF51. These CPPs 
were able to form stable non-covalent complexes with pDNA, siRNA and SCO, 
with the size between 60–140 nm in MQ water and 75–177 nm when serum was 
present. Introduction of either modification resulted in a CPP with greater effi-
cacy than stearyl-TP10, but the use of both modifications in the same sequence 
resulted in a CPP with the highest efficacy.  
As NF51 was the most efficient CPP out of three tested peptides the de-
livery with NF51 was investigated more thoroughly. It was tested for the de-
livery of pDNA in several cell lines, including hard to transfect cells and also in 
serum containing conditions. Even when serum was present, NF51 was able to 
mediate pDNA delivery into cells resulting in a high level of reporter gene 
expression from the delivered cargo. In addition to this, NF51 was able to de-
liver not only pDNA, but also siRNA and SCO resulting in efficient gene 
downregulation or reporter gene splice correction. The limited increase in 
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expression after addition of CQ and also TEM analysis revealed that NF51 has 
lysosomotropic properties and when associated with a cargo it is able to mediate 
endosomal escape after internalization. NF51 was tested for the applicability in 
QMCF protein production system as the delivery vector and was able to trans-
fect the whole cell population and was more efficient even at lower DNA con-
centrations than commercially available reagents.  
Out of designed CPPs, NF51 was the most efficient delivery vector for NAs 
and is applicable for the use in different cell lines. 
 
 
4.2. NickFect1 and NickFect51 differ in uptake mechanism 
and intracellular trafficking (Paper II) 
CPPs have been used to deliver variety of cargoes across the cell membranes, 
resulting in a high biological effect from the delivered cargo. However, the 
mechanism by which this effect is mediated is still vague. Understanding the 
circumstances behind the delivery enables to overcome the limitations of CPP-
based transport vectors. 
Modifications in the CPP stearyl-TP10 were introduced to the peptide se-
quence to increase the plasmid carrying efficacy of CPPs. NF1 and NF51 (a 
CPP designed and tested in paper I) were compared based on their complex 
formation, uptake mechanism and also intracellular trafficking of the formed 
complexes. In NF1, an extra negative charge was introduced by Y substitution 
phosphorylated tyrosine. Modifications in the NF1 and NF51 sequence influ-
enced the nanoparticle formation, internalization route and intracellular traf-
ficking of the nanoparticles, but for both CPPs the final biological effect gained 
from delivered cargo was similarly high. The transfection efficiency and pre-
vious work showed that NF1 and NF51 were the most efficient CPPs in the line 
designed with similar modifications [51, paper I]. In paper II we aimed to shed 
light on the mechanisms behind the efficiency. Both CPPs were able to form 
complexes with pDNA using the non-covalent strategy. In water NF1 and NF51 
mixed with pDNA form nanoparticles with the size of <100 nm and addition of 
serum resulted in the increase of size and a negative surface charge. However, 
the serum did not significantly decrease the stability of the complexes. The 
negative surface charge of the complexes in the presence of serum components 
may play a role in the internalization of complexes. Although the negatively 
charged nanoparticle surface may repulse with the negative charges of the 
plasma membrane, scavenger receptors with low specificity may mediate the 
uptake of negatively charged particles. A role in the uptake of PF14/NA com-
plexes has been shown for SCARA3 and SCARA5 previously [50, 122]. For 
NF1/pDNA and NF51/pDNA the use of scavenger receptor inhibitors and 
downregulation of SCARA 3 and 5 resulted in decreased biological effect. This 
indicates that SCARAs are involved in the uptake of the formed complexes.  
The ability of CPPs to form a stable complex with the pDNA was assessed 
by adding heparin sodium salt to the pre-formed complexes. This revealed that 
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NF51/pDNA complexes were more stable to the replacement of pDNA by hepa-
rin, indicating that the formed complexes were more resistant to decomp-
lexation compared to NF1/pDNA complexes. Similar dissociation tendencies 
were seen for NF1/pDNA also when observing the behavior of the complexes in 
the cells. For NF1, the fluorescence signals from peptide and pDNA were less 
co-localized in the same compartments than for NF51/pDNA. In addition, 
NF51/pDNA harnessed macropinocytosis as the main entry route and according 
to the endosomal compartment separation NF51/pDNA complexes stayed in 
less acidic endosomal compartments for extended period, compared to 
NF1/pDNA. NF51/pDNA complexes used different internalization mechanism 
than NF1/pDNA, as revealed by TEM (transmission electron microscopy) study. 
While NF51/pDNA formed large aggregates on the cell surface associated with 
macropinocytosis by membrane ruffling, NF1/pDNA complexes interacted with 
membrane as small clusters and were detected in the proximity of membrane 
pits and small ruffles. This indicates that NF1/pDNA may harness distinct 
endocytotic pathways simultaneously.  
After endocytosis, the CPP/pDNA complexes are confined in the endo-
cytotic vesicles and if the CPP is not able to disrupt the endosomal membranes, 
the complexes are routed for degradation to Lys. The escaping ability was 
assessed by the use of the lysosomotropic agent, chloroquine (CQ), during 
transfection. If CQ had effect on the increase of biological effect, then com-
plexes were not co-localized with the CQ and not entrapped in the Lys. The 
addition of CQ did not significantly increase the biological effect gained for 
NF51/pDNA complexes, indicating that they are mainly located in EEs or 
escaped before reaching Lys. In the case of NF1/pDNA, the pDNA is located in 
LEs and Lys. Similar difference was detected when analyzing endosomal com-
partments separated form transfected cells. 
Although having largely similar sequences, the modifications introduced in 
each peptide led to different mechanisms of action when delivering pDNA into 
the cell. NF51/pDNA was able to internalize cells rapidly and remain in EEs for 
longer periods, giving more time for complexes to escape from the endosomes 
and reach cytosol. However, the stability of complexes reduces the unpacking 
of the cargo and decreases the amount of free pDNA from which gene could be 
expressed. NF1/pDNA complexes were more prone to disscoiate prematurely, 
leading the pDNA to the Lys for degradation. At the same time the proportion 
of complexes that is able to escape endosomes and reach cytosol is more easily 
dissociated and pDNA is free for following gene expression. For both peptides 
different limiting factors were proposed, but they both led to high gene expres-
sion in in vitro conditions and the understanding of CPP-mediated delivery 
gives basis for further development of the vectors. 
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4.3. Intracellular trafficking of NF1 and NF51 complexes 
with pDNA (Paper III) 
The intracellular trafficking and more importantly, the endosomal release of 
CPP/cargo complexes are processes not thoroughly studied for nanocomplexes. 
Several methods have been developed over the years, but all of them have some 
disadvantages. In paper III we aimed to find a suitable method to track the 
intracellular trafficking of the CPP/pDNA nanocomplexes and reveal the simi-
larities and differences behind NF1 and NF51 as the transporters of pDNA.  
Cells internalize CPP/cargo complexes predominantly via a pathway of 
endocytosis, which leads the entrapment of complexes in endosomal vesicles. 
To have a biological effect, the cargo has to be released from these vesicles and 
transported to the target site. For plasmid, the target organelle is the cell 
nucleus; therefore the CPP may have to mediate the transport of pDNA through 
the nucleus envelopes in addition to the plasma membrane and endosomes. 
Another strategy is for delivery into the nucleus is the CPP/pDNA complex 
release to the cytosol and during mitosis the pDNA can be incorporated to the 
cell nucleus. Before all these steps, the CPP/cargo complex has to escape endo-
somes; otherwise they are degraded in the LEs and Lys. 
NickFects are able to deliver pDNA into the cells in large quantities. After 
4 h almost 80% of pDNA was located in the cell and cellular compartments. To 
determine which endosomal mechanism NFs use, inhibitors were used to disrupt 
the endosome maturation, formation or acidification. For NF51/pDNA com-
plexes, the inhibition of endosome acidification led to a decrease in the reporter 
gene expression, indicating that NF51 needed the change in acidity in order to 
gain high levels of gene expression from delivered plasmid. The role of 
acidification may also be for the inducement of dissociation of more stable 
NF51/pDNA complexes. For NF1, as it was located in the acidic Lys, the inhi-
bition of acidification may have a different role, as it increases the time for the 
complexes to escape so pDNA is still intact and not degraded by Lys enzymes. 
Analysis of cellular contents after separation of endosomal compartments 
revealed that the complexes formed with NF51 and NF1 were located dif-
ferently and the fraction of NF51/pDNA in endosomes decreased in time more 
than with NF1/pDNA, indicating that NF51/pDNA complexes were more 
capable to escape from the endosomes. At the same time, the proportion of 
complexes in Lys was higher with NF1/pDNA than with NF51/pDNA, showing 
that complexes formed with NF1 were more prone for degradation. The func-
tionality of the pDNA in separated endosomes was checked by transfecting new 
cells, and it showed that the pDNA detected from EEs had the highest biologi-
cal effect gained from pDNA. To confirm the results obtained with cen-
trifugation method, single particle tracking (SPT) and co-localization of labelled 
vesicles and labelled pDNA was used. Firstly, the complex formation ability or 
size did not significantly increase when using labeled Cy5-pDNA, as confirmed 
with the gel electrophoresis and DLS. SPT revealed that there was a difference 
in internalization and localization of the complexes formed with NF1 and NF51. 
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For NF1/Cy5–pDNA a considerable amount of pDNA was co-located with LEs 
whereas NF51/Cy5–pDNA co-located mainly with EEs. In the case of com-
plexes formed with NF1, the percentage of co-localization events with LEs 
increased more rapidly than with EEs whereas the percentage in EEs reached a 
plateau at higher point (70 min post-treatment) and remained fairly stable. For 
NF1/Cy5–pDNA, a higher amount of co-localization events with Lys was 
detected already at 15 min post-treatment in comparison to NF51/Cy5–pDNA. 
Both NF51 and NF1 mediated efficient delivery of pDNA to the cell and 
enable expression from the delivered cargo, but the route of action differed. 
Endosomal transport and acidification of endosomal compartments play a role 
in delivery of pDNA. The final expression gained from the pDNA remained 
high, although NF1/pDNA complexes reach LEs and Lys faster and in larger 
proportion. For NF1/pDNA complexes the degradation in Lys in one of the 
hindering factors. NF51 mediated delivery enabled the pDNA to stay in the EEs 
for longer time period, giving higher opportunity for endosomal escape and 
bypassing the degradation in Lys. Both CPPs were efficient for pDNA delivery 
into different cell lines, although the characteristics of each should be taken into 
account when harnessing them for macromolecule delivery. Understanding the 
distinction between CPPs and relating them to differences in physico-chemical 
properties helps to implement modified CPPs with higher specificity for mac-
romolecule delivery. In addition, SPT and centrifugation methods have proven 
to be valuable for understanding intracellular events leading to the biological 
effect from the cargo. 
 
 
4.4. The binding of CPP and siRNA, complex formation and 
stability of formed complexes leads to biological activity 
of delivered siRNA (Paper IV) 
Delivery of bioactive cargoes holds great potential, but the lack of efficient 
delivery methods for the NAs curbs their use. The first step towards delivery is 
the formation of CPP/cargo complexes and it relies on the physical and chemi-
cal properties of the CPP and also the cargo. In order to deliver bioactive car-
goes into the cells efficiently, the CPP has to form stable nanoparticles that at 
the same time are able to release the cargo at the right target site. The complex 
formation and uptake mechanism of CPP/pDNA has been studied extensively. 
The siRNAs propose different challenges for the carrier and the complex for-
mation. The siRNA complex formation cannot be based only on the previous 
knowledge of plasmid DNA behavior. 
In the paper IV the previously developed CPPs belonging to the PepFect 
and NickFect family were included in addition to TP10 and NickFect57 to 
compare the effect of modifications in the sequence, net charge, complex for-
mation, stability and their correlations with the biological effect from the 
delivered siRNA. PF6 had the highest charge density compared to other tested 
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CPPs and due to the chloroquine moieties has a pH dependent change of net 
charge. The high number of charges enabled PF6 to form complexes with 
siRNA at lower molar ratios and results in stable nanoparticles. The complex 
formation was investigated using gel electrophoresis, fluorescent dye inter-
calation assay and also iTC. All methods indicated that the mechanism of PF6 
differs when compared to other CPPs. In addition, the CQ moiety increases the 
stability of PF6 to proteolytic enzymes.  
The formation of complex itself did not ensure efficient delivery. NF51, 
NF57 and PF3 had a similar net charge and N-terminal stearyl modification and 
did not differ significantly in the binding to siRNA according to gel electro-
phoresis and PG assay results. Although PF3 formed complexes with siRNA, 
only low levels of gene knockdown were achieved. This could be linked to 
premature dissociation of complexes and insufficient destabilization of endo-
somal membranes. PF14 needed less peptide to form complexes with siRNA, 
but the complexes were unstable to enzymatic degradation and siRNA was 
released. The resistance of complexes to degradation and avoiding premature 
dissociation of siRNA is fundamental for CPP-mediated cargo delivery; 
however, this is usually compromised by the CPP or cargo cleavage before 
reaching the target. Intracellular uptake and protection of siRNA from degra-
dation may be the leading limitations, because siRNA is prone to degradation 
by nucleases. To test the stability of the complexes heparin displacement assay 
and enzymatic degradation were used. Complexes formed with PF6/siRNA 
proved the most stable to enzymatic degradation and also to heparin displace-
ment. PF6 is able to pack siRNA in a manner that it is not accessible to 
nucleases, therefore protecting it from premature degradation.  
The presence of free peptide may be one of the forces behind the internali-
zation and also endosomal escape. During intracellular trafficking in the endo-
somes, the pH is decreased and CPP net charge increases. This increase leads to 
reorganization of CPP/siRNA complexes and increase of free peptide fraction 
capable of interacting with membranes. Based on the results we proposed a 
model of nanoparticle formation with PF6 and siRNA, where the CPPs inter-
acting directly with siRNA for the core of the particle and additional CPP is 
needed to form a shell that is able to interact with receptors and membranes. In 
addition, as the number of CPPs in the core changes when pH decreases or 
increases and leads to a change in CPP/siRNA complex stability, the siRNA is 
released from the acidic compartments to the cytosol. 
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5. CONCLUSIONS 
This thesis is dedicated to the investigation of CPP-based delivery vectors for 
complex formation with NAs and their delivery into the cells. The CPPs used in 
this thesis enable non-covalent nanoparticle formation and are thoroughly 
studied for complex formation, stability and to the premature dissociation of the 
CPP/cargo complexes for the in vitro delivery. In addition to comparison 
between the CPPs, two intrinsically different cargoes were used to elucidate the 
challenges of the delivery that either poses. They key findings are listed below. 
 
Paper I 
• The replacing of K7 with an O7 and the continuation of synthesis through 
the δ-amino group of O7 side chain resulted in a highly efficient CPP, 
NF51, for the delivery of NAs. Introduction of either modification alone 
into stearyl-TP10 increased the efficacy of the CPP. 
• NF51, NF53 and NF61 were able to form nanoparticles with pDNA, siRNA 
and SCO and mediate their transport into the cells and subsequent gene 
expression, gene downregulation or non-functional reporter gene splice cor-
rection.  
• NF51 was an efficient pDNA delivery vector for tested adherent, suspen-
sion and primary cells. 
• NF51 could be applied as a transfection reagent for QMCF technology. 
 
Paper II 
• Modifications introduced into the stearyl-TP10 sequence, such as a kinked 
structure or the addition of a negative charge, lead to the significantly dif-
ferent CPPs NF1 and NF51. Both peptides were able to exhibit high 
delivery efficiency and high biological effect from the delivered pDNA. 
• Either CPP has a different challenge to overcome in order to mediate 
delivery. 
• Scavenger receptors are involved in the internalization of the NF/pDNA 
complexes. 
• NF1/pDNA complexes use several endocytosis pathways simultaneously. 
NF51/pDNA complexes harness macropinocytosis as the main entry path-
way. 
• The premature dissociation of the NF1/pDNA complexes is the biggest 
challenge for NF1 mediated delivery. Internalizaed complexes are routed to 
Lys for degradation. The endosomal escape of the NF1/pDNA complexes is 
limited, compared to the NF51/pDNA complexes. 
• Plasmid DNA is forming more stable complexes with NF51 than with NF1. 
NF51 promotes the stay of the complexes in the EEs. Although endosomal 
escape is efficient, the released complexes are not dissociated as easily, 
therefore gene expression from pDNA is hindered. 
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Paper III 
• Separation of endosomes from transfected cells enables to determine the 
location of the delivered pDNA without labeling the CPP or the cargo. 
Single particle tracking and analysis of co-localization of Cy5-pDNA with 
endosomal compartments is a fast and precise method to pinpoint the 
localization of pDNA and also the events of endosomal release. Both 
methods can be used to determine the trafficking and endosomal release of 
the CPP/NA complexes. 
• Intracellular trafficking of the NF51/pDNA and the NF1/pDNA complexes 
differs, arising from the properties of the complexes. NF51/pDNA is 
located in the EEs for longer and the transport efficiency depends both on 
endosomal transport and the acidification of the endosomes. NF1/pDNA is 
rapidly routed to the LEs and Lys, but the proportion that is released to the 
cytosol is able to dissociate and release pDNA for subsequent gene expres-
sion. 
 
  
Paper IV 
• The CPPs NF51 and PF14 that are suitable for pDNA transfection are not as 
efficient for siRNA delivery.  
• Electrostatic interaction driven by the net charge of the peptide and nega-
tively charged NA backbone is the main force that promotes the complex 
formation, but hydrophobicity and peptide secondary structure of NFs and 
PFs affect the complex stability and the final biological effect from the 
delivered cargo. 
• PF6 has the highest net charge and stability to degradation by proteases. 
The pH sensitive moiety leads to an increase in the net charge when pH 
decreases and causes a rearrangement of the formed complex. High net 
charge accompanied with resistance to degradation enables the formation of 
stable CPP/siRNA nanoparticles and is the pre-requisite for efficient siRNA 
delivery into cells.  
• We propose that CPP and siRNA are arranged in a particle, forming a core 
and a shell. These structures dynamically reorganize depending on the envi-
ronmental pH changes. 
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SUMMARY IN ESTONIAN 
Rakku tungivate peptiidide ja nukleiinhapetega  
moodustatud nanokompleksidega seotud protsessid:  
kuidas, miks, mis ja kuhu 
Nukleiinhapped omavad rakus olulist rolli nii pärilikkuse säilitamisel, geenide 
ekspressioonil kui ka geenide regulatsioonil. Nukleiinhappemolekule ja nende 
modifitseeritud analooge võiks potentsiaalselt kasutada ka geeniteraapiaks või 
uute geenide viimiseks rakkudesse, kus neid tavaliselt ei leidu. Nukleiinhapete 
kasutamise eeliseks on nende bioloogiline sobivus, kuid nukleiinhapete tera-
peutilist ja biotehnoloogilist kasutust piirab nende limiteeritud sisenemine rak-
kudesse ja kudedesse. Lisaks sellele lagundatakse vabad nukleiinhappemole-
kulid nii rakuvälises kui ka – siseses keskkonnas kiirelt. Sellest tulenevalt on 
nukleiinhapete laialdasemaks kasutamiseks vajalik efektiivse ning ohutu trans-
portmeetodi rakendamine. 
Viirusvektorite ja füüsikaliste meetodite kõrval on nukleiinhapete transpor-
diks kasutatud ka keemilisi vektoreid. Üheks suure potentsiaaliga vektorite tüü-
biks on rakku tungivad peptiidid. Neid iseloomustab võime siseneda rakkudesse 
ning sinna kaasa transportida ka endaga seotud lastmolekule. Rakku sise-
nevatele peptiididele on võimalik lasti siduda kovalentselt ja mittekovalentselt. 
Mittekovalentsel seondumisel on oluliseks peptiidis leiduvatel aminohapetel 
positiivselt laetud kõrvalrühmade olemasolu ning interaktsioon nukleiinhapete 
fosfaatselgroo negatiivsete laengutega. Lisaks sellele on hüdrofoobse rasv-
happejäägi saba lisamine võimaldanud suurendada moodustunud komplekside 
stabiilsust ning interaktsioone membraanidega.  
Nukleiinhappemolekulid erinevad nii suuruselt, kujult, kui ka struktuurilt, 
mistõttu on ühe, universaalse, transporteri leidmine keerukas. Plasmiidid on 
suured rõngasmolekulid, mille mittekovalentsel seondumisel on oluliseks vektori 
poolt indutseeritud plasmiidi kokku pakkimine nanopartikliks. Väiksemad 
oligonukleotiidi ja RNA molekulid, vajavad nukleaasidele kättesaadavate osade 
tõttu kaitset lagundamise eest.  
Antud doktoritöö eesmärgiks on selgitada rakku sisenevate peptiidide ja 
nukleiinhapete vahel mittekovalentselt moodustunud komplekside füüsikalisi 
ning keemilisi omadusi, stabiilsust ning ka sisenemismehhanisme ja kompleksi-
dega seotud protsesse rakus. Selleks võrreldi rakku sisenevaid peptiide, mis 
kuuluvad kimäärse peptiidi transportaan modifikatsioonide hulka ning mille 
puhul on eelnevalt näidatud võimet transportida rakku nukleiinhappeid. Last-
molekulidena kasutati peamiselt plasmiidset DNA-d ja siRNA-sid. 
Esimeses artiklis testitakse kahe erineva modifikatsiooni mõju rakku sise-
neva peptiidi transfektsiooniefektiivsusele. Lastmolekulidena kasutatakse nii 
pDNA-s, siRNA-t kui ka vaheltlõikust (splicing) korrigeerivaid oligonukleo-
tiide. Plasmiidi transfektsiooni efektiivsust NF51-ga testitakse lisaks tava-
päraselt kasutatavatele HeLa ja CHO rakuliinidele ka teistes rakuliinides, mida 
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loetakse raskemini transfekteeritavateks. Lisaks testitakse NF51-e kasutust 
QMCF tootmistehnoloogias transporterina. 
Teises artiklis kirjeldatakse rakku sisenevate peptiidide NF1 ja NF51 
komplekside stabiilsust, sisenemisteed rakku ning liikumist rakus ning kuidas 
on nendesse peptiidide järjestustesse viidud modifikatsioonid mõjutanud nende 
omadusi transporterina. Mõlemad peptiidid suudavad plasmiidi viia rakkudesse 
ning tagada kõrge ekspressioonitase plasmiidilt, kuid see, kuidas kumbki vektor 
selleni jõuab, on erinev. Kummagi peptiidi puhul ilmnevad kitsaskohad nende 
transpordiviisil kas komplekside ebastabiilsuses, kiires degradeerimises lüso-
soomides või kompleksides, mis ei suuda piisavalt efektiivselt plasmiidi komp-
leksist sihtkohas vabastada.  
Kolmandas artiklis võrreldakse kahte meetodit, mis võimaldavad täpsemalt 
jälgida sündmusi, mis järgnevad komplekside sisenemisele rakku. Kummalgi 
meetodil on eelised ja puudused, kuid mõlema puhul avaldub erinevus NF1 ja 
NF51 vahendatud plasmiidi transpordis, mis toetavad esimeses töös kirjeldatud 
sündmusi. 
Neljandas artiklis kasutatakse lastmolekulina sünteetilisi siRNA molekule, 
sest need võimaldavad spetsiifilisemat geeni mõjutamist ning on oluliseks RNA 
interferentsi tekitamiseks rakus terapeutilisel või biotehnoloogilisel eesmärgil. 
Töö käigus selgub, et transporterid, mis suudavad kõige efektiivsemalt trans-
portida plasmiidset DNAd, ei ole kõige sobivamad siRNA transpordiks. Lisaks 
sellele, tuginedes tulemustele, pakutakse mudel, kuidas toimub siRNA ja pep-
tiidi vaheline interaktsioon ning komplekside moodustumine. 
Antud töös on püütud selgitada peptiidide vahendatud nukleiinhapete trans-
pordi eripärasid, liikumist rakus ning komplekside moodustumist, millele saaks 
tugineda peptiidide edasine disain.  
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